Download 2010-11 Regional Cancer Program Progress Report

Regional Cancer Program – LHIN 4
Quality and Performance Management
Carol Rand, MSc, MA
Director, Regional Cancer Program
September 17, 2014
Cancer Care Ontario
•
•
•
•
Directs and oversees $700M
Implements cancer prevention and screening programs
Develops and implements quality improvements and standards
Uses electronic information and technology to improve safety,
quality, efficiency, accessibility and accountability
• Plans cancer services to meet current and future needs
working with the LHINs
• Knowledge translation
2
Regional Cancer Programs & Performance
Management
Established in 2005 to:
• Respond to local issues and needs
• Act on provincial quality standards for cancer services locally
• Improve wait times, access and quality by managing and
coordinating care across local and regional providers
Confidential DRAFT only
3
Draft- Regional Cancer Program Committee Structure
President & CEO HHS
R. MacIsaac
CEO, Cancer Care Ontario
Dr. M. Sherar
Vice President, Regional Cancer Programs
G. Matheson
Executive V.P. Clinical Operations
B. Flaherty
President, Juravinski Cancer Centre
Regional Vice President, Cancer Care Ontario
Dr. R. Meyer
Director, Regional Cancer Programs
C. Rand
Regional Cancer Program Priorities & Planning Committee
Regional Communities
of Practice
Networks/Leads
HHS Integrated Cancer
Program Quality Council
Dr R. Meyer
Pathology
Dr. V. Alexopoulou
Primary Care
Dr. M. Davis
Breast Imaging
Dr. T. Minuk
Endoscopy
Dr. B. Lumb
Cervical
Dr. Dustin Costescu
Cancer Imaging
Dr. M. Midia
Regional Clinical Quality Systemic
Dr. J. Goffin
Regional Clinical Quality
Radiation
Dr. J. Wright
Psychosocial Oncology
L. Learn
Patient Education
C. Bennett
Aboriginal
J. Matone/L. Styres-Loft
NHS/WFCC Cancer Council
Dr. J. Giesbrecht
SJHC Cancer Council
W. Doyle
JBMH Cancer Council
N. LaBelle
Regional Health Planner
Performance/Data Analyst
Quality Specialist
Regional Cancer Program Coordinator
BGH Cancer Council
L. Rinaldi
Regional Program
Clinical/
Administrative Leads
Surgical Oncology
Dr. V. Tandan
C. Rand
Systemic Therapy
Dr. P. Ellis
C. Rand
Radiation Therapy
Dr. J. Wright
C. Potvin
Prevention & Integrated
Cancer Screening
C. Rand
OBSP Breast Imaging
Dr. T. Minuk
High Risk Genetics
Dr. K. Zbuk
Palliative Care
C. Rand
CCO Quality Initiatives
Quality Initiatives One-time Funding $336,793
• Diagnostic Assessment Program (DAP) $173,099
• RSTP Quality Improvement Funding $26,429
• Multidisciplinary Cancer Conferences (MCC) $ 56,365
• Ontario Cancer Symptom Management Collaborative (OCSMC) $50,000
• SOP - Regional Quality Improvement Incentive $9,000
• Pathology and Laboratory Medicine - Stakeholder Engagement $5,000
• Radiation Treatment Peer Review QA Data Collection Pilot $6,900
• Advancing Priorities Of The Declaration Of Partnership $10,000
5
CCO Quality Initiatives
Regional Medical Leads Funding $710,000
• Regional Primary Care Lead - Cancer Screening $50,000
• Regional Primary Care Lead - Cancer Care $50,000
• Regional Breast Imaging Lead $50,000
• Regional Colorectal Screening/GI Endoscopy Lead $ 50,000
• Regional Cervical Screening/Colposcopy Lead $50,000
• Regional Imaging Quality Lead $50,000
• Regional Surgical Oncology Lead $110,000
• Regional Pathology Lead $50,000
• Regional Radiation Lead $50,000
• Regional Systemic Treatment Quality Lead $50,000
• Regional Patient Education Lead $25,000
• Regional Psychosocial Oncology Lead $25,000
• Regional Palliative Care Lead $50,000
• Patient Navigator Stipend $100,000
• Regional Aboriginal Cancer Lead $50,000
6
Provincial Summary (Data as of March 31, 2014)
Notes:
• Overall Provincial Ranking is the sum of all rankings relative to all other Regions normalized to number of measures available. Non-RCC indicators and volumes are excluded.
= Performance appears to be at or above target
= Performance appears to be below target, but is not significant (i.e. the confidence interval spans the target)
= Performance is significantly below the target (i.e. the confidence interval is entirely below the target)
= There was a statistically significant increase in performance over the previous period
= There was a statistically significant decrease in performance over the previous period
No arrow = There was no significant increase or decrease in performance over the previous period
7
Radiation Treatment – Referral to Consult
8
Radiation Treatment – Ready to Treat to Treatment
% seen within target (1, 7, 14 days) - Last 12 months
9
Radiation Volumes and Wait Times
10,253
10
Systemic Treatment – Referral to Consult (RCC)
11
Systemic Treatment – Referral to Consult (non-RCC)
12
Systemic Treatment – Consult to Treatment (RCC)
13
Systemic Treatment – Consult to Treatment (non-RCC)
14
Systemic Volumes and Wait Times
15
Cancer Surgery – Decision to Treat to Treatment (RCC)
16
Cancer Surgery – Decision to Treat to Treatment (nonRCC)
17
Cancer Surgery Volumes and Wait Times
18
OBSP Wait Times – With Tissue Biopsy
Note:
1.
This indicator cannot be separated into Toronto Central South and Toronto Central North. As a result, performance for Toronto Central is shown.
19
OBSP Wait Times – Without Tissue Biopsy
Note:
1.
This indicator cannot be separated into Toronto Central South and Toronto Central North. As a result, performance for Toronto Central is shown.
20
OBSP Volumes and Wait Times
Note:
1.
This indicator cannot be separated into Toronto Central South and Toronto Central North. As a result, performance for Toronto Central is shown.
21
CCC FOBT Participation Rate
(September 2013 vs. September 2012)
Note:
1.
This indicator cannot be separated into Toronto Central South and Toronto Central North. As a result, performance for Toronto Central is shown.
22
DAP – Referral to Diagnosis or Rule Out
% of patients diagnosed or ruled out within 28 days - Last 12 months
23
Pathology Report Turn Around Time – Colorectal Cancer
% reports received within 14 days - Last 12 months
Note:
1.
North East rates affected by a data quality issue. Reporting interface at Health Sciences North down for 5 weeks during the 3rd quarter and as a result, no cases during
that window met the 14 day target.
24
Symptom Management – ESAS
% screened for symptom severity using ESAS – Last 12 months
25
Symptom Management – ESAS
26
Patient Experience – Emotional Support (RCC)
% of patients who reported being put in touch with other providers to help
with their anxieties or fears in the last 6 months - Apr 2013 to Sept 2013
27
Patient Experience – Emotional Support (non RCC)
% of patients who reported being put in touch with other providers to help
with their anxieties or fears in the last 6 months - Apr 2013 to Sept 2013
28
Multidisciplinary Cancer Conferences (RCC)
% adherence to minimum MCCs standards criteria – 2013/14 Q3
% adherence - FQ1 2013/14 vs. FQ3 212/13
29
Multidisciplinary Cancer Conferences (non-RCC)
% adherence to minimum MCCs standards criteria – 2013/14 Q3
30